Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

Partnership Will Utilize Foresight’s Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene’s ALPHA3 Trial SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 -- Allogene...

Related Keywords

Zachary Roberts ,Sara Head ,David Chang ,Axicabtagene Ciloleucel ,Christine Cassiano ,Leslie Bryant ,Polatuzumab Vedotin ,Madeleine Goldstein ,Jake Chabon ,Twitter ,Nasdaq ,Linkedin ,Allogene Therapeutics Inc ,Co Ting Keh ,Technology To Identify Patients For Enrollment ,Corporate Affairs Brand Strategy ,Research Development ,Drug Administration ,Partnership Will Utilize Foresight ,Identify Patients ,Foresight Diagnostics ,Chief Executive Officer ,Executive Vice President ,Chief Medical Officer ,About Allogene ,South San Francisco ,Cemacabtagene Ansegedleucel ,Previously Known ,Regenerative Medicine Advanced Therapy ,Forward Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Allogene Therapeutics ,Investor Contact ,Chief Corporate Affairs ,Brand Strategy ,Allogene Media Contacts ,Previously Untreated Diffuse Largeb Cell ,Term Follow Up ,Acute Lymphoblastic ,Largeb Cell ,Markets ,